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Human herpesvirus 8 (HHV-8; also designated Kaposi’s sarcoma-associated herpesvirus) is the likely
etiological agent of Kaposi’s sarcoma (KS). HHV-8 encodes a latent nuclear antigen (LNA) which is the
product of the viral gene orf 73. LNA is recognized by most infected patient sera and is the basis of current
immunofluorescence assays used in epidemiological studies of HHV-8 infection. Here we describe the charac-
terization of four monoclonal antibodies raised to the C-terminal third of LNA–glutathione S-transferase
fusion proteins. These monoclonal antibodies recognized discrete linear epitopes within the C terminus and
repetitive region of LNA, detected antigen in primary effusion lymphoma (PEL) cells, and precipitated a 220-
to 230-kDa protein doublet corresponding to LNA from HHV-8-infected PEL cell lines. In situ immunocyto-
chemistry of KS lesions with these antibodies show that LNA is extensively expressed in KS spindle cells.
Human herpesvirus 8 (HHV-8; also designated Kaposi’s sar-
coma-associated herpesvirus) is the first known human mem-
ber of the genus Rhadinovirus within the Herpesviridae (9).
HHV-8 is related to the New World primate rhadinovirus
herpesvirus saimiri (1), a rhesus macaque rhadinovirus (10),
and macaque retroperitoneal fibromatosis virus isolates Mn
and Mm (25). More recently, equine herpesvirus 2, bovine
herpesvirus 4, alcelaphine herpesvirus 1, and murine herpes-
virus 68 have been tentatively classified as rhadinoviruses.
HHV-8 is associated with all epidemiological forms of Kaposi’s
sarcoma (KS) (4, 6, 28). HHV-8 is also associated with primary
effusion lymphoma (PEL) (7) and a subset of multicentric
Castleman’s disease (12, 30). Epidemiological studies using
PCR detection of specific HHV-8 genomic sequences, and
immunological assays for antibodies to the major latent nu-
clear antigen (LNA) and other antigens, have shown that
HHV-8 largely fulfills epidemiological criteria for causation in
KS (5, 13, 14, 16, 19, 20, 22, 29, 32).
Sera from HHV-8-infected individuals react with a specific
nuclear antigen in latently infected PEL cell lines which is
characterized by a punctate nuclear immunofluorescence pat-
tern (19). Screening of cDNA libraries with an HHV-8-positive
patient serum identified this nuclear antigen as the product of
the viral gene open reading frame 73 (orf73), and the encoded
protein was designated LNA or LANA (17, 18, 24). LNA is
expressed from a latently controlled 5.32-kb transcript that also
encodes the viral cyclin (v-Cyc) and v-FLIP (11, 18). The
5.32-kb latent transcript is spliced to form a 1.7-kb transcript
that encodes only v-Cyc and v-FLIP (11, 18, 27). The predicted
LNA protein is 1,162 amino acids long and has a theoretical
molecular mass of 135 kDa. In contrast to LNA’s predicted
molecular size, the protein has an apparent molecular size of
220 to 230 kDa when analyzed by Western blotting (13, 18, 24).
LNA can be divided into three domains: an N-terminal 337-
amino-acid domain; an extremely hydrophilic central domain
of 585 amino acids consisting of multiple repeat elements pre-
dominantly containing the charge polar amino acids glutamine,
glutamic acid, and asparagine; and a C-terminal 240-amino-
acid domain. In contrast to the central domain, the N- and
C-terminal domains are rich in basic amino acids. The differ-
ently charged domains of the protein may in part explain the
aberrant running of LNA on sodium dodecyl sulfate (SDS)-
polyacrylamide gels.
LNA is thus far the only latent nuclear antigen described for
HHV-8 and has no obvious sequence identity to known pro-
teins. However, the immunogenic nature, nuclear localization,
and latent expression of LNA suggest that this protein is anal-
ogous to Epstein-Barr virus (EBV) nuclear antigens (EBNAs).
EBNAs have a pivotal role in maintenance and replication of
the virus episome and transforming cells. Insights into the
function of LNA could be essential in the understanding of
HHV-8 latency and tumor formation. Here we describe the
characterization of four monoclonal antibodies (MAbs) to the
C terminus of orf73. These antibodies recognize distinct linear
epitopes of LNA, confirm that orf73 encodes the major latent
nuclear antigen of HHV-8, and detect LNA expression in PEL
cell lines and in KS nodules.
Generation of MAbs against LNA. Glutathione S-trans-
ferase (GST) proteins of the C terminus of orf73 (GST-C14
and GST-C17) were described previously (18). Briefly, GST-
C14 contains amino acids 803 to 1113 of orf73 encompassing
126 amino acids of the central repeat domain as well as 184
amino acids of the C-terminal basic domain (Fig. 1). GST-C17
contains amino acids 803 to 942 comprised almost entirely of
repetitive coding sequence. GST-C14 served as the backbone
for making further defined deletions of the C terminus of orf73
by using three unique restriction enzyme sites. GST-C7 was
constructed by digesting GST-C14 with NruI (in orf73) and
NotI (in pGEX-4T3 [Pharmacia]), followed by end repair and
ligation. GST-C11 was constructed by digesting GST-C14 with
NruI and NotI and cloning the restriction fragment into the
SmaI and NotI sites of the vector pGEX-4T1 (Pharmacia).
GST-C11 served as the backbone for two further deletion
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clones. GST-C9 and GST-C10 were constructed by restriction
enzyme digestion with StuI plus NotI and AgeI plus NotI, re-
spectively, followed by end repair and ligation. Recombinant
protein-expressing clones were confirmed by DNA sequence
analysis. In addition, two polyhistidine fusion proteins were
constructed. The entire BamHI-to-NotI C-terminal restriction
fragment from GST-C14 was cloned into the polyhistidine fu-
sion protein vector pTrcHis2C (Invitrogen) via BamHI and
HindIII following conversion of the NotI and HindIII sites to
blunt ends to produce clone TH-C14. The NruI-to-NotI frag-
ment corresponding to GST-C11 was PCR amplified and
cloned to produce TH-NN. Large-scale production and single-
step affinity purification of fusion proteins (GST [Pharmacia]
and polyhistidine [Invitrogen]) were performed according to
the manufacturer’s instructions. All fusion proteins were rec-
ognized by antibodies to GST (B14; Santa Cruz) or to the Myc
epitope present in the polyhistidine fusion proteins (data not
shown). Pools of affinity-purified GST fusion proteins were
used for intraperitoneal immunization of rats at 3-week inter-
vals. Three days following the final boost, rats were sacrificed
to obtain splenocytes for hybridoma production by standard
procedures. Hybridomas were screened by enzyme-linked im-
munosorbent assay (ELISA) and Western blotted against the
polyhistidine fusion protein TH-C14, and positive hybridomas
were subcloned. Following a second ELISA screening, reactive
MAbs were bulk cultured and antibodies were purified from
culture supernatants by antibody affinity chromatography. This
procedure produced MAbs ranging in concentration from 1 to
2 mg/ml. The isotype of each MAb was determined by standard
methods. Four MAbs, LN20, LN53, LN69, and LN72, with
isotypes immunoglobulin M (IgM), IgG2c, IgG1 and IgG2b,
respectively, were raised to these GST fusion proteins.
Mapping of the epitopes recognized by the MAbs. The an-
tigenic epitopes recognized by these MAbs were mapped by
using the panel of GST and polyhistidine fusion proteins (Fig.
1) in an ELISA format. Briefly, fusion proteins were immobi-
lized onto 96-well plates (Immulon 2; Dynex Technologies) in
10 mM sodium phosphate buffer (pH 7.0) by overnight incu-
bation at 4°C. A standard ELISA protocol was followed, using
appropriate dilutions of anti-LNA MAbs and 1:2,000 dilution
of goat anti-rat alkaline phosphatase-conjugated secondary an-
tibody (Sera-Lab) as described elsewhere (15). Reactions were
visualized by using p-nitrophenyl phosphate (Sigma Fast) ac-
cording to the manufacturer’s instructions. Antibody LN20
recognized all recombinant proteins to various degrees, as
shown by reactivity to clones of the repetitive and nonrepeti-
tive C-terminal regions (Fig. 1). The recombinant proteins
represent a nonoverlapping set and contain no apparent com-
mon epitopes, which suggests that LN20 is a mixed antibody
population, requiring further rounds of monocloning. Anti-
body LN53 recognized recombinant proteins GST-C14, GST-
C17, GST-C7, and TH-C14 (Fig. 1), demonstrating that the
FIG. 1. Fusion protein mapping of LNA MAbs. The C-terminal locations of six GST-LNA fusion proteins (GST-C14, -C7, -C17, -C11, -C9, and -C10) and two
histidine-tagged fusion proteins (TH-C14 and TH-NN) are shown relative to that of full-length LNA. Numbers represent amino acids relative to the putative start
methionine at codon 127296 of the published HHV-8 genome (26). The hatched box represents the extent of the repetitive coding region of LNA. Restriction enzyme
sites NruI, AgeI, and StuI used to construct the fusion protein clones are indicated. The reactivity of each MAb to each fusion protein is shown as A410 above background
of greater than 0.5 absorbance units (111), between 0.1 and 0.5 absorbance units (11), or between 0.02 and 0.1 absorbance units (1). The epitope-mapped position
of each MAb is indicated on TH-C14. The epitopes are EQEQE for LN53, EVDYPV for LN72, and THPKKPHPRYQQ for LN69.










minimum epitope recognized by this antibody is the repetitive
region of orf73 encompassing GCT-C17 or the 13 amino acids
C terminal to the repetitive region. Antibody LN69 recognized
only GST-C9, GST-C10, TH-C14, and TH-NN. This mapped
the LN69 minimal epitope to the 37 amino acids (amino acids
981 to 1018 of LNA) present in GST-C10 (Fig. 1). It is unclear
why LN69 did not recognize GST-C14 or GST-C11, as both
contained the minimal epitope. Antibody LN72 recognized
GST-C14 and -C7 but not GST-C17 and thus recognizes a
39-amino-acid region (from amino acids 942 to 981) of LNA.
To confirm and further refine the minimal epitopes for each
MAb, multiple overlapping peptides corresponding to the re-
gions of LNA identified by ELISA were synthesized by using
the SPOTS system (Genosys). Peptide mapping revealed that
LN69 recognized the epitope THPKKPHPRYQQ, LN72 rec-
ognized the epitope EVDYPV, and LN53 recognized the
epitope EQEQE. These epitopes are contained within the
minimal LNA recombinant proteins identified by ELISA, thus
confirming the binding sites of the three MAbs. The LN53
epitope is contained within the repetitive region of LNA, re-
sulting in 23 copies of the LN53 epitope in full-length LNA.
Database searching revealed that this epitope is present in
human proteins, including the alpha-type calcitonin gene-re-
lated peptide precursor (P06881), drebrin (Q16643), transla-
tion initiation factor IF-2 (P46199), and aldehyde dehydroge-
nase (P30838), but only in single copy. The LN69 and LN72
epitopes have only partial homologies to known cellular pro-
teins.
Immunoprecipitation and immunofluorescence assay (IFA)
of HHV-8 LNA. Previous studies have shown that the authentic
LNA protein encoded in PEL cell lines is a doublet with an
apparent molecular mass of 220 to 230 kDa (13, 18, 24), in
contrast to the predicted molecular mass of 135 kDa. The
reasons for the size difference are unclear. MAbs LN53, LN69,
and LN72 produced in this study were used to immunoprecipi-
tate LNA from the PEL cell line BC-3 (2). Briefly, cells were
starved for 1 h in methionine- and cysteine-free RPMI (Sigma)
supplemented with 10% dialyzed fetal calf serum (FCS;
Gibco), washed, and then labeled for 4 h in fresh medium
FIG. 2. Immunoprecipitation and Western blot analyses using LNA MAbs.
(a) Immunoprecipitates from 107 BC-3 cells or Ramos cells per lane were
resolved on SDS–8% polyacrylamide gels. LN53 was able to precipitate a 220- to
230-kDa doublet corresponding to LNA. Pooled antibody isotype controls to
HIV gp120 for each LNA MAb as well as Protein G-Sepharose-only immuno-
precipitation controls (Control and Protein G lanes, respectively) were used in
identical immunoprecipitations. (b) Western blot of 2 3 105 cell equivalents of
total protein extract from BC-3 (2) and Ramos cells detected with LNA MAb
LN20. A doublet of 220 to 230 kDa, and a smaller reactive band of approximately
180 kDa (marked on blot) are seen. Identical lanes were detected with an anti-rat
alkaline phosphatase-conjugated secondary antibody as a control. The same
results were obtained for LN53 and LN72 (data not shown).
FIG. 3. LNA MAbs react with nuclear bodies in PEL cells. MAbs LN20 (a), LN53 (b), and LN72 (c) all react by IFA to nuclear antigenic structures in BCP-1 cells
(3, 14) identical to those detected with HHV-8-positive KS patient serum (f). Antibody LN53 did not react with nuclear antigens present in control Daudi (d) or Ramos
(e) cells. LN20 and LN72 were also negative on control cells (not shown). The bar in panel a applies to all panels.










supplemented with a mixture of [35S]methionine and [35S]cys-
teine (70 mCi/ml in medium; Amersham Pro-mix) plus 10%
dialyzed FCS. After being washed, the cell pellets were lysed
for 30 min on ice in 1 ml of lysis buffer (150 mM NaCl, 1.0%
Nonidet P-40, 50 mM Tris-HCl [pH 8]) supplemented with the
protease inhibitor phenylmethylsulfonyl fluoride (100 mg/ml),
pepstatin A (0.7 mg/ml), and leupeptin (5 mg/ml), and lysates
were cleared by centrifugation at 14,000 3 g for 10 min at 4°C.
Extracts from the equivalent of 107 cells were precleared for
1 h with protein G-Sepharose beads (Sigma) equilibrated in
PBST (phosphate-buffered saline [PBS] plus 1% Triton X-100)
and then immunoprecipitated overnight at 4°C with protein
G-Sepharose beads precoated with saturating amounts of the
indicated MAbs. Immunoprecipitates were washed and loaded
onto an SDS–8% polyacrylamide gel. Only MAb LN53 was
able to precipitate a doublet protein of 220 to 230 kDa. LN69
and LN72 precipitated proteins present in both BC-3 and con-
trol Ramos cells but did not precipitate LNA (Fig. 2a). The
identity of the major 105- to 110-kDa protein precipitated by
LN69 from both cell types is unclear, and a database search
using the LN69 epitope failed to identify any candidate pro-
teins. Antibodies LN20, LN53, and LN72 reacted with a pro-
tein doublet of 220 to 230 kDa by Western blotting (Fig. 2b).
In addition, a protein of approximately 180 kDa was recog-
nized by the antibodies by Western blotting (Fig. 2b). Reac-
tivity to proteins of this size had previously been seen in West-
ern blots with HHV-8-positive patient sera but had not been
assigned as LNA specific (13, 18, 24).
IFAs are used extensively in the seroepidemiology of
HHV-8 (6). Under standard IFA conditions, MAbs LN20,
LN53, and LN72 were able to produce the punctate nuclear
fluorescence pattern associated with HHV-8 LNA in PEL cell
lines (Fig. 3a to c). The antibodies were specific for HHV-8
LNA, with no apparent cross-reaction to other proteins
present in control B-cell lines Daudi and Ramos (Fig. 3d and
e). The best antibody for IFA was LN53, which could be
diluted to 1:10,000 without significantly affecting the charac-
teristic LNA IFA pattern in BCP-1 cells. All antibodies were
also able to recognize LNA expressed in BCP-1 cells by fluo-
rescence-activated cell sorting analysis (FACS) analysis (Fig.
4a). No cross-reactivity was observed for each antibody with
the control B-cell lines Ramos (EBV negative) and Daudi
(EBV positive) (representative controls [Fig. 4b]). FACS anal-
ysis was also performed with LN53 on one other PEL, BC-3,
and on the HHV-8/EBV-coinfected B-cell lymphoma line
HBL-6 (Fig. 4b). The BC-3 cell line exhibited the characteristic
FACS pattern showing that the majority of cells express LNA.
Analysis of HBL-6 showed that most cells expressed LNA, but
a subpopulation appeared to be nonexpressing. Whether this is
a consequence of HHV-8/EBV coinfection is currently being
studied.
HHV-8 LNA is abundantly expressed in KS lesions. To date
few protein-specific antisera or MAbs have been raised to
HHV-8 proteins. Antibodies to virus-encoded interleukin-6
(vIL6) (21) and to orf26 (23) and orf59 (8) protein products
have been used to study protein expression in a variety of
HHV-8-infected cell types. However, no antibodies to latent
proteins have been used in such studies. LN53 and LN72 but
not LN20 and LN69 reacted with antigen in paraffin-embedded
KS tissue. As MAb LN53 was assessed to be the best antibody
raised, it was used further in the examination of the expression
of HHV-8 LNA in KS lesions. LNA was extensively expressed
in late-stage nodular KS, predominantly in cells of spindle-
shaped morphology (Fig. 5b to d). LNA-positive cells account
for more than 90% of all cells present in nodular KS lesions.
The staining was exclusively nuclear, and in most cases a punc-
tate nuclear staining, reminiscent of the nuclear IFA staining
seen in PEL cell lines (Fig. 3), was seen (Fig. 5d). No expres-
FIG. 4. FACS profile of LNA MAbs on HHV-8-infected cells. The MAbs were tested by FACS on cell lines BCP-1, BC-3, HBL-6, Daudi, and Ramos; 5 3 105 cells
were permeabilized, and LNA antibodies were used at the dilution of 1:100. The cells were incubated for 1 h with individual antibodies in PBS–0.05% saponin–1%
FCS), washed three times in PBS–0.1% (vol/vol) Tween, and incubated for 1 h with rabbit anti-rat fluorescein isothiocyanate-conjugated (DAKO) secondary antibody.
Analysis was performed on a FACS 440 (Becton Dickinson). Fluorescent intensity is expressed on an arbitrary logarithmic scale. Black histograms represent
antibody-stained cells, and white histograms represent secondary antibody conjugate controls. (a) All antibodies detected the LNA-expressing cell population in BCP-1
cells. (b) Antibody LN53 does not detect LNA in the negative control cells Ramos (EBV negative) and Daudi (EBV positive) but does detect the LNA-positive
population in the HHV-8-infected BC-3 and HBL-6 cell lines. All other antibodies are negative for the control cell lines (data not shown).










sion of LNA was detected in surrounding normal dermis (Fig.
5b). No staining was observed in the control tumors angiosar-
coma and hemangioma (not shown).
Conclusions. One of the predominant proteins encoded by
HHV-8 during the latent phase of the virus life cycle is LNA,
the product of orf73 (17, 18, 24). Here we describe the char-
acterization of four MAbs to the C terminus of LNA. The
properties of the MAbs are summarized in Table 1. These
antibodies recognize LNA in immunofluorescence, immuno-
precipitation, in situ immunocytochemistry, and FACS analy-
ses. Three of the MAbs recognized different discrete epitopes
in the C terminus of LNA. The most reactive MAb, LN53,
recognized the minimal epitope EQEQE present as 23 copies
in LNA. This provides an explanation for this antibody’s high
reactivity in all assays used, as the repeat units of LNA should
provide multiple epitopes for the antibody. The majority of the
EQEQE epitopes are located in the extensive leucine zipper
motif of LNA. Structure predictions of this region and knowl-
edge of coiled-coil leucine zipper structures suggest that the
EQEQE motif is located in a regular pattern on the leucine
zipper alpha helices, allowing accessibility of the antibody un-
der native protein folding conditions. This correlates with the
ability of LN53 to immunoprecipitate LNA from cell extracts.
Immunoprecipitation studies confirmed that LNA exists as a
protein doublet of 220 to 230 kDa in BC-3 cells (Fig. 2a). A
protein of similar size was recognized by Western blotting (Fig.
2b). As with HHV-8-positive patient sera, the LNA antibodies
produce a punctate immunofluorescence pattern in PEL cell
FIG. 5. LN53 reactivity to LNA in nodular KS. Immunocytochemistry was performed on a paraffin-embedded tumor from classical KS. Permeabilization was
performed by microwave. Negative control biopsies were from angiosarcomas and hemangiomas (not shown). After incubation with normal rabbit serum (DAKO),
MAbs were applied for 1 h at 22°C followed by two washes in PBS–0.1% (vol/vol) Tween. The secondary biotin-conjugated antibody (rabbit anti-rat; DAKO) was
applied for 30 min followed by washing. Antibody reactions were visualized with streptavidine-alkaline phosphatase (Vector Laboratories) and a substrate red
chromogen (Vector). Adjacent sections were stained by standard methods. (a) Hematoxylin and eosin staining showing KS nodule (left) and surrounding dermis (right).
(b) Adjacent sections stained with LN53 showing clear demarcation between LNA expression in the KS lesion and not in the surrounding dermis (magnification, 340).
Almost all spindle-shaped cells are positive for LNA (360) (c), with a stippling pattern reminiscent of the staining of PEL cells (3160) (d).
TABLE 1. Properties of MAbs to LNA
Antibody Isotype
Reaction
ELISA Western blottinga Immunoprecipitationa IFAb Immunocytochemistryc
LN20 IgM 1 1 NDd 1 2
LN53 IgG2c 1 1 1 1 1
LN69 IgG1 1 2 2 2 2
LN72 IgG2b 1 1 2 1 1
a BC-3 cells.
b BCP-1 cells.
c Paraffin-embedded KS lesion.
d ND, not determined.










lines (Fig. 3). Using LN53, we demonstrated extensive LNA
expression in nodular KS. There is a clear demarcation be-
tween the KS nodule and surrounding dermis (Fig. 5b). The
majority of cells showed punctate nuclear staining reminiscent
of the nuclear staining in HHV-8-positive PEL cells (Fig. 5d),
which suggests that the nuclear structures containing LNA
present in PEL cells are also present in HHV-8-infected KS
spindle cells. LNA expression has recently been demonstrated
in all tissue and cell types associated with HHV-8 infection and
disease (12). At present it is unclear what LNA associates with
in the nuclei of latently infected cells. Studies have shown that
LNA remains associated with chromosomes during mitosis
(31). This feature is reminiscent of EBNA1, which is chromatin
associated in both interphase and metaphase nuclei (31). How-
ever, in cells coinfected with EBV and HHV-8, EBNA1 and
LNA do not colocalize, indicating that they occupy different
nuclear domains (31). A careful study of colocalization and
protein association with LNA by using MAb LN53 should
provide insights into the function of LNA in HHV-8 latency.
The expression pattern of all known HHV-8 genes in the
PEL cell line BC-1 has shown that relatively few transcripts are
abundantly produced during HHV-8 latency (27). Using anti-
body LN53, we show expression of one such latent protein,
LNA, in both PEL cell lines and KS tumors. Antibodies to
other, predominantly lytic HHV-8 proteins, namely, the prod-
ucts of orf59 (8), a putative DNA polymerase accessory pro-
tein, and orf26, a 32-kDa inducible protein (23), have been
described. Antisera to vIL6 showed expression in approxi-
mately 50% of uninduced BCP-1 cells and primary ascitic
PELs, suggesting constitutive vIL6 expression in latently in-
fected PEL cells (21). However, vIL6 protein was rarely de-
tected in KS lesions, and when detected, it accounted for less
than 2% of HHV-8-infected cells, indicating that vIL6 could be
differentially expressed in hematopoietic versus mesenchymal
cells. Whether LNA is involved, through interaction with dif-
ferent tissue-specific cellular factors, in the differential expres-
sion of HHV-8 genes and whether this contributes to HHV-8
pathogenesis remain to be determined. LNA is the first latent
protein described for HHV-8, and use of our MAbs to under-
stand its function is likely to be crucial to the understanding of
HHV-8 cellular transformation and virus pathogenesis.
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